Skip to main content
Clinical Trials/NCT06507228
NCT06507228RecruitingNot Applicable

North West London Pebble Pathway: Automated OSA Diagnosis

Patrik Bachtiger2 sites in 1 country200 target enrollmentStarted: July 7, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
200
Locations
2
Primary Endpoint
Time to diagnosis

Study Overview

Brief Summary

Patients with obstructive sleep apnoea (OSA) wait up to two years for a diagnostic test. Early diagnosis enables optimal treatment, mitigating risks including heart failure, lung disease, and stroke. Current diagnostic approaches are expensive (£391), time-consuming (>1-hour interpretation), uncomfortable (cables/tubes/wires), and inequitable (multiple hospital visits). Overcoming all these limitations, we have designed and will investigate a straigh-to-test automated diagnostic pathway for OSA. This will use the AcuPebble, a miniature wearable acoustic sensor and the first regulated technology for automated, at-home diagnosis. The test is cheap (< £100); time-saving; endorsed by patients, and accessible (posted directly to patients). This project will measure the impact of a potentially transformative, innovative, and scalable diagnostic pathway using AcuPebble technology.

Detailed Description

The investigators are conducting a prospective implementation and health economic study of a novel straight-to-test (STT) clinical diagnostic pathway for OSA, using a novel, regulatory-approved wearable medical device for automated diagnosis of OSA in the home setting (AcuPebble SA100). The setting is real-world direct clinical care, with participation from three NHS sleep medicine centres servicing the North West London region.

Inclusion criteria is primary care referrals for OSA investigation were triaged onto the pathway based on predetermined criteria, compared to a historical cohort of patients undergoing STT using cardiorespiratory polygraphy (CR-PG) technology serving as a control group. The primary outcome is time-to-diagnosis. Secondary outcomes include NHS cost-saving per patient; surrogates for health equity (e.g. test completion rates, time/cost of journeys saved); and carbon footprint reduction from averted patient journeys (sustainability).

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • OSA testing referral from primary care

Exclusion Criteria

  • Unable to follow test instructions

Outcomes

Primary Outcomes

Time to diagnosis

Time Frame: 12 months

Time to diagnosis vs. historical control group

Secondary Outcomes

  • Cost saving per test(12 months)
  • Test completion rate(12 months)
  • Sustainability impacts by carbon footprint reduction(12 months)
  • Financial saving to patients from cutting journeys associated with appointments(12 months)
  • Time saving to patients from cutting journeys associated with appointments(12 months)

Investigators

Sponsor
Patrik Bachtiger
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Patrik Bachtiger

NIHR Academic Clinical Lecturer

Imperial College London

Study Sites (2)

Loading locations...

Similar Trials